Perspective Therapeutics Future Growth
Future criteria checks 2/6
Perspective Therapeutics is forecast to grow earnings and revenue by 1.2% and 82% per annum respectively while EPS is expected to grow by 11.6% per annum.
Key information
1.2%
Earnings growth rate
11.6%
EPS growth rate
Biotechs earnings growth | 34.8% |
Revenue growth rate | 82.0% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 30 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 0 | -83 | -53 | -74 | 6 |
12/31/2025 | 0 | -71 | -84 | -71 | 9 |
12/31/2024 | 1 | -54 | -65 | -45 | 8 |
6/30/2024 | 1 | -52 | -25 | -14 | N/A |
3/31/2024 | 2 | -50 | -23 | -13 | N/A |
12/31/2023 | 1 | -37 | -38 | -37 | N/A |
9/30/2023 | 1 | -20 | -33 | -32 | N/A |
6/30/2023 | 1 | -13 | -25 | -24 | N/A |
3/31/2023 | 3 | -6 | -19 | -19 | N/A |
12/31/2022 | 5 | -8 | -11 | -10 | N/A |
9/30/2022 | 10 | -9 | -8 | -7 | N/A |
6/30/2022 | N/A | -6 | -8 | -8 | N/A |
3/31/2022 | 11 | -6 | -6 | -6 | N/A |
12/31/2021 | 11 | -6 | -5 | -5 | N/A |
9/30/2021 | 10 | -5 | -5 | -5 | N/A |
6/30/2021 | 10 | -3 | -3 | -3 | N/A |
3/31/2021 | 10 | -4 | -3 | -3 | N/A |
12/31/2020 | 10 | -3 | -3 | -3 | N/A |
9/30/2020 | 10 | -3 | -4 | -3 | N/A |
6/30/2020 | 10 | -3 | -4 | -4 | N/A |
3/31/2020 | 9 | -3 | -4 | -4 | N/A |
12/31/2019 | 8 | -4 | -5 | -4 | N/A |
9/30/2019 | 8 | -4 | -5 | -4 | N/A |
6/30/2019 | 7 | -5 | -5 | -5 | N/A |
3/31/2019 | 7 | -6 | -6 | -6 | N/A |
12/31/2018 | 7 | -7 | -6 | -5 | N/A |
9/30/2018 | 6 | -7 | -6 | -6 | N/A |
6/30/2018 | 6 | -7 | -6 | -6 | N/A |
3/31/2018 | 6 | -6 | N/A | -5 | N/A |
12/31/2017 | 5 | -6 | N/A | -6 | N/A |
9/30/2017 | 5 | -6 | N/A | -6 | N/A |
6/30/2017 | 5 | -6 | N/A | -6 | N/A |
3/31/2017 | 5 | -6 | N/A | -6 | N/A |
12/31/2016 | 4 | -5 | N/A | -5 | N/A |
9/30/2016 | 5 | -5 | N/A | -4 | N/A |
6/30/2016 | 5 | -5 | N/A | -4 | N/A |
3/31/2016 | 5 | -5 | N/A | -3 | N/A |
12/31/2015 | 5 | -4 | N/A | -4 | N/A |
9/30/2015 | 5 | -4 | N/A | -3 | N/A |
6/30/2015 | 5 | -4 | N/A | -4 | N/A |
3/31/2015 | 4 | -4 | N/A | -4 | N/A |
12/31/2014 | 4 | -5 | N/A | -3 | N/A |
9/30/2014 | 4 | -5 | N/A | -3 | N/A |
6/30/2014 | 4 | -7 | N/A | -3 | N/A |
3/31/2014 | 4 | -6 | N/A | -3 | N/A |
12/31/2013 | 5 | -5 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AAJ0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AAJ0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AAJ0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AAJ0's revenue (82% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: AAJ0's revenue (82% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AAJ0's Return on Equity is forecast to be high in 3 years time